Vijaya Diagnostic Centre Limited (VIJAYA) - Total Liabilities

Latest as of September 2025: Rs5.26 Billion INR ≈ $56.84 Million USD

Based on the latest financial reports, Vijaya Diagnostic Centre Limited (VIJAYA) has total liabilities worth Rs5.26 Billion INR (≈ $56.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VIJAYA cash generation efficiency to assess how effectively this company generates cash.

Vijaya Diagnostic Centre Limited - Total Liabilities Trend (2019–2025)

This chart illustrates how Vijaya Diagnostic Centre Limited's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Vijaya Diagnostic Centre Limited to evaluate the company's liquid asset resilience ratio.

Vijaya Diagnostic Centre Limited Competitors by Total Liabilities

The table below lists competitors of Vijaya Diagnostic Centre Limited ranked by their total liabilities.

Company Country Total Liabilities
Oil Refineries Ltd.
TA:ORL
Israel ILA2.56 Billion
C3 Ai Inc
NYSE:AI
USA $189.41 Million
Austal Ltd
AU:ASB
Australia AU$1.64 Billion
Beijing Topnew Info And Tech Co Ltd
SHE:300895
China CN¥120.18 Million
Topsec Technologies Group Inc
SHE:002212
China CN¥1.48 Billion
Lightwave Logic Inc
NASDAQ:LWLG
USA $7.02 Million
Yeni Gimat Gayrimenkul Yatirim Ortakligi AS
IS:YGGYO
Turkey TL5.98 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Vijaya Diagnostic Centre Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VIJAYA market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.00 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vijaya Diagnostic Centre Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vijaya Diagnostic Centre Limited (2019–2025)

The table below shows the annual total liabilities of Vijaya Diagnostic Centre Limited from 2019 to 2025.

Year Total Liabilities Change
2025-03-31 Rs4.74 Billion
≈ $51.31 Million
+46.97%
2024-03-31 Rs3.23 Billion
≈ $34.91 Million
+5.24%
2023-03-31 Rs3.07 Billion
≈ $33.18 Million
+25.77%
2022-03-31 Rs2.44 Billion
≈ $26.38 Million
+34.24%
2021-03-31 Rs1.82 Billion
≈ $19.65 Million
-12.69%
2020-03-31 Rs2.08 Billion
≈ $22.51 Million
+4.36%
2019-03-31 Rs1.99 Billion
≈ $21.57 Million
--

About Vijaya Diagnostic Centre Limited

NSE:VIJAYA India Diagnostics & Research
Market Cap
$1.26 Billion
Rs116.23 Billion INR
Market Cap Rank
#8122 Global
#382 in India
Share Price
Rs1129.60
Change (1 day)
+1.40%
52-Week Range
Rs861.40 - Rs1141.35
All Time High
Rs1241.80
About

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T ser… Read more